HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Guang Yang, Sara Buhrlage, Li Tan, Xia Liu, Jie Chen, Lian Xu, Nicholas Tsakmaklis, Jiaji G. Chen, Christopher J. Patterson, Jennifer R. Brown, Jorge J. Castillo, Wei Zhang, Xiaofeng Zhang, Shuai Liu, Philip Cohen, Zachary R. Hunter, Nathanael S. Gray, Steven P. Treon (Lead / Corresponding author)